Key facts
- It has raised $2.5M; the latest was Later Stage VC ($1.0M) in Jun 2025.
- Notable investors include Y Combinator, Innovate UK, Gaingels, The NHS Innovation Accelerator, 007 Venture Partners — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Digistain
- ·The full record, as it builds
Funding rounds
No funding rounds for Digistain are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Digistain
Developer of tumor profiling technology designed to predict the risk of recurrence in breast cancer patients. The company's technology utilizes advanced AI and spectral signature analysis of key biomarkers from biopsy samples, generating comprehensive data points, enabling healthcare providers to expand access to crucial cancer recurrence prediction tests for a broader market.
- Sector
- Healthcare
- HQ
- Newport Pagnell, United Kingdom
- Founded
- 2019
- Employees
- 19
- Website
- digistain.co.uk/
- Ownership
- Privately Held (backing)
Digistain doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Digistain shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Digistain in its N-PORT filings yet. We sweep new filings monthly.